Publications
Addressing the systemic challenges of underinvestment in prevention
8 June 2026
Prevention of ill-health is an underexploited tool for protecting health systems…
The impact of inflation on incremental costs in HTA
4 June 2026
Inflation reshapes the economic landscape in which new treatments are evaluated.…
The value of fast diagnostics in time-critical infections
20 April 2026
Advancing earlier intervention in time‑critical infections Sepsis continues to…
Evaluating novel antimicrobials within EU joint clinical assessments
16 April 2026
Antimicrobial resistance (AMR) is a growing global health and economic threat.…
Insights
Compared to what? How the choice of comparator affects new medicines
14 September 2026
Comparator choice shapes health technology assessment: it sets the benchmark a…
Why President Trump’s generic drug tariffs are unlikely to fix America’s supply problem
13 August 2026
America's dependence on foreign generic manufacturing is a real national…
What the first EU JCA reveals about assessing precision oncology
28 July 2026
We explore how the first JCA provides insights into the longstanding…
What is a life worth in climate policy? It depends on who you ask
22 July 2026
The ECOnomic Evaluation for Climate Action (ECO-CHICA) consensus guidance is now…
Robust analysis, real-world problems
OHE research supports pragmatic solutions and stronger policy decisions
Areas of expertise
OHE’s expertise covers a wide range of topics
Health Technology Assessment (HTA)
Compared to what? How the choice of comparator affects new medicines
Comparator choice shapes health technology assessment: it sets the benchmark a new medicine is assessed against, driving…
Around the World in HTAs: Spain – Closer than ever, but not quite yet
Spain has introduced its first national legal framework for health technology assessment (HTA) through Royal Decree…
Drug Development/R&D
Is the revised Congressional Budget Office model of new drug development fit for purpose?
As U.S. drug-pricing policy changes accelerate, policymakers need reliable ways to understand how reduced pharmaceutical…
Evaluating novel antimicrobials within EU joint clinical assessments
Antimicrobial resistance (AMR) is a growing global health and economic threat. It is responsible for an additional 9.5…
Prevention
The cost of inaction on LDL cholesterol
This Insight is based on the WHA79 panel discussion "Lowering Cholesterol, Increasing Impact: The Case for Earlier Action…
Addressing the systemic challenges of underinvestment in prevention
Prevention of ill-health is an underexploited tool for protecting health systems and societies. It offers the potential to…
EQ-5D and PROMs
Seven reflections on the UK EQ-5D-5L value set – and what comes next
The long-awaited UK EQ-5D-5L value set has been published, marking a key moment for health technology assessment. Its…
Understanding the preferences of people with acute leukemia for different health outcomes
When we want to understand or measure someone’s “health-related quality-of-life”, we typically ask them to describe…
Events
OHE events sharing innovation and insights
Carer quality of life in HTA: from measurement to economic models
17 September 2026, 1:00pm
Informal carers play a vital role in patient outcomes, but capturing their quality of life in HTA remains a persistent…
